Vivet Therapeutics to Present Key Findings on its Gene Therapy Program forCerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting
Paris, France, November 14, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotechcompany developing novel and long-lasting gene therapies for rare inherited liver metabolicdisorders, today